top of page
Jan 302 min read
Granules strengthens ADHD portfolio with FDA approval for Lisdexamfetamine Dimesylate Capsules
Granules India received the final approval from the US FDA for its ANDA for Lisdexamfetamine Dimesylate Capsules in strengths of 10-70 mg
Dec 17, 20242 min read
Granules India Limited announces FDA approval for ADHD treatment, addressing drug shortages in the US
Granules India received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)
bottom of page